Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions: Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history; Behavioral · Other · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Delirium
Interventions: IV acetaminophen & IV propofol, IV acetaminophen & IV dexmedetomidine, IV propofol & placebo, IV dexmedetomidine & placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Burn, Pain, Dissociation, Opioid
Interventions: Ketamine, 0.9% NaCl; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Knee Osteoarthritis
Interventions: Amniotic Suspension Allograft, Placebo; Biological · Drug
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 38
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more

Conditions: There is no Focus on Any Specific Condition
Interventions: Peripheral intravenous catheter placement, Blood draw, Peripheral intravenous catheter, To keep open (TKO) infusion of 0.9% normal saline; Procedure · Other · Device + 1 more
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 90 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hip Pain
Interventions: bacteriostatic saline, buffered lidocaine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Rhytides
Interventions: PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA; Drug
Lead sponsor: Lupo Center for Aesthetic and General Dermatology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Lower Urinary Tract Symptoms
Interventions: Lactobacillus rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Osteoarthritis
Interventions: Ropivacaine, Normal saline, Methylprednisolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Tranexamic Acid, Saline; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Intracranial Atherosclerosis
Interventions: Feraheme; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Propofol Injection Pain
Interventions: Passive arm elevation, Normal saline, Lidocaine, Propofol, Sham arm elevation; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Beta-hydroxybutyrate, Normal Saline; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Suicide, Attempted
Interventions: Ketamine Hydrochloride, Saline, CAMS Therapy; Drug · Behavioral
Lead sponsor: Tatiana Falcone, MD; Other
Eligibility: 14 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obstetric Labour, Premature
Interventions: Retosiban solution for Infusion, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cystic Fibrosis
Interventions: Hypertonic Saline, Isotonic Saline, Indium-DTPA, Technetium Sulfur Colloid; Drug
Lead sponsor: Tim Corcoran; Other
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Interventions: TTAX03, Saline; Biological
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more

Conditions: Hemorrhagic Fever With Renal Syndrome
Interventions: HTNV/PUUV DNA vaccine, Placebo, TriGrid Delivery System (TDS); Biological · Device
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: TEPEZZA, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Dengue Fever
Interventions: TAK-003, Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 923 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more

Conditions: Active C. Difficile Colitis
Interventions: Microbiota Transplantation (FMT); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2036
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridium Difficile Infection
Interventions: C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 9,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 142
States / cities: Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more

Search by objective public record fields.

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery

Low-Dose Ketamine Infusion During Burn Wound Care

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

Antegrade Versus Retrograde IV for Blood Draws

Comparison of Bacteriostatic Saline to Buffered Lidocaine for Ultrasound Guided Hip Joint Injection Local Anesthesia

Metabolic Effects of Angiotensin-(1-7)

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis

Impact of Topical Tranexamic Acid in Breast Reconstruction

Predicting Stroke Risk in ICAD With Novel MRI

Arm Elevation for Prevention of Propofol Injection Pain

Brain Ketone Metabolism in Type 1 Diabetes

Ketamine Treatment of Youth Suicide Attempters

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

Multilevel Models of Therapeutic Response in the Lungs

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection